Pre-made Romilkimab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL13;IL4 therapeutic antibody, Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Romilkimab (SAR156597), however, “is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,” the researchers explain.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-492-1mg	1mg	Inquiry
GMP-Bios-ab-492-10mg	10mg	Inquiry
GMP-Bios-ab-492-100mg	100mg	Inquiry
GMP-Bios-ab-492-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody
INN Name	Romilkimab
Target	IL13;IL4
Format	Bispecific Dual Variable Domain IG
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2017
Year Recommended	2018
Companies	Sanofi
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Idiopathic pulmonary fibrosis
Development Tech	na